{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T03:37:21Z","timestamp":1782963441374,"version":"3.54.5"},"reference-count":47,"publisher":"Georg Thieme Verlag KG","issue":"09","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Res (Stuttg)"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This review offers an in-depth evaluation of Lasmiditan, a novel and\n                        selective 5-HT1F receptor agonist, representing a significant breakthrough\n                        in migraine pharmacotherapy. Unlike existing reviews, this article\n                        consolidates all critical aspects of Lasmiditan into a single, authoritative\n                        source encompassing both extensive literature analysis and original findings\n                        from our laboratory to provide researchers and clinicians with streamlined\n                        access to essential data and minimize the need for exhaustive literature\n                        searches.<\/jats:p>\n                  <jats:p>The review provides a comprehensive assessment of Lasmiditan, highlighting\n                        its physicochemical properties, pharmacological profile, mechanism of\n                        action, clinical efficacy and safety, drug interactions, and emerging\n                        insights from cell line studies. Lasmiditan\u2019s solubility influences its\n                        bioavailability and efficacy. It acts centrally without vascular\n                        constriction, unlike traditional therapies. Clinical trials confirm its\n                        rapid, effective migraine relief with mild side effects. Minimal drug\n                        interactions support its use in polypharmacy. Cell studies reveal its\n                        receptor activity and transport mechanisms, enhancing therapeutic\n                        understanding.<\/jats:p>\n                  <jats:p>Lasmiditan represents a groundbreaking addition to migraine therapeutics,\n                        providing a targeted, non-vasoconstrictive alternative. Its safety,\n                        tolerability, and efficacy make it a strong alternative for patients\n                        unsuitable for traditional treatments, with ongoing research likely to\n                        expand its clinical relevance.<\/jats:p>","DOI":"10.1055\/a-2695-0263","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T23:17:57Z","timestamp":1758755877000},"page":"347-361","source":"Crossref","is-referenced-by-count":1,"title":["Lasmiditan in Migraine Management: An Advanced Review of Its\n                    Pharmacological Paradigm, Clinical Applications, Safety Considerations, Drug\n                    Interaction Spectrum, and Regulatory Approval"],"prefix":"10.1055","volume":"75","author":[{"given":"Krutuja R.","family":"Chougule","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, KLE College of Pharmacy,\n                    Belagavi, KLE Academy of Higher Education and Research, Nehru Nagar, Belagavi,\n                    Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7458-8842","authenticated-orcid":false,"given":"Archana S.","family":"Patil","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, KLE College of Pharmacy,\n                    Belagavi, KLE Academy of Higher Education and Research, Nehru Nagar, Belagavi,\n                    Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swapnil","family":"Patil","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, KLE College of Pharmacy,\n                    Belagavi, KLE Academy of Higher Education and Research, Nehru Nagar, Belagavi,\n                    Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,9,24]]},"reference":[{"issue":"12","key":"ref1","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.3390\/pharmaceutics12121180","article-title":"Pharmacokinetics, pharmacodynamics and drug\u2013drug interactions of new\n                    anti-migraine drugs\u2014Lasmiditan, gepants, and calcitonin-gene-related peptide\n                    (CGRP) receptor monoclonal antibodies","volume":"12","author":"D Szkutnik Fiedler","year":"2020","journal-title":"Pharmaceutics"},{"issue":"05","key":"ref2","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.3390\/molecules27051680","article-title":"The role of serotonin neurotransmission in gastrointestinal tract and\n                    pharmacotherapy","volume":"27","author":"T Guzel","year":"2022","journal-title":"Molecules."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s00210-024-03329-8","article-title":"Lasmiditan ameliorates serotonergic itch in mice: possible involvement of 5-HT1F\n                    receptors","volume":"398","author":"A Afrooghe","year":"2024","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"10","key":"ref4","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1177\/0333102410370873","article-title":"Preclinical pharmacological profile of the selective 5-HT1F receptor agonist\n                    Lasmiditan","volume":"30","author":"D L Nelson","year":"2010","journal-title":"Cephalalgia"},{"issue":"13","key":"ref5","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1080\/14656566.2017.1361406","article-title":"The safety and efficacy of the 5-HT1F receptor agonist Lasmiditan in the acute\n                    treatment of migraine","volume":"18","author":"B Raffaelli","year":"2017","journal-title":"Expert Opin Pharmacother"},{"issue":"01","key":"ref6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s10194-020-01132-3","article-title":"Lasmiditan mechanism of action\u2013review of a selective 5-HT1F agonist","volume":"21","author":"D B Clemow","year":"2020","journal-title":"J Headache Pain"},{"issue":"18","key":"ref7","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/s40265-019-01225-7","article-title":"Lasmiditan: First Approval","volume":"79","author":"Y N Lamb","year":"2019","journal-title":"Drugs"},{"issue":"05","key":"ref8","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1177\/87551225211024630","article-title":"Lasmiditan: acute migraine treatment without vasoconstriction. A review","volume":"37","author":"J K Beauchene","year":"2021","journal-title":"J Pharm Technol"},{"issue":"02","key":"ref9","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1080\/14656566.2019.1694004","article-title":"Profiling lasmiditan as a treatment option for migraine","volume":"21","author":"M Curto","year":"2020","journal-title":"Expert Opin Pharmacother"},{"issue":"06","key":"ref10","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1046\/j.1468-2982.1997.1706631.x","article-title":"Migraine therapy: relationship between serotonergic contractile receptors in\n                    canine and rabbit saphenous veins to human cerebral and coronary arteries","volume":"17","author":"M L Cohen","year":"1997","journal-title":"Cephalalgia"},{"issue":"24","key":"ref11","doi-asserted-by":"publisher","first-page":"4681","DOI":"10.1111\/bph.14832","article-title":"Characterization of binding, functional activity, and contractile responses of\n                    the selective 5-HT1F receptor agonist lasmiditan","volume":"176","author":"E Rubio-Beltran","year":"2019","journal-title":"Br J Pharmacol"},{"issue":"05","key":"ref12","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1097\/j.pain.0000000000001801","article-title":"Lasmiditan inhibits calcitonin gene-related peptide release in the rodent\n                    trigeminovascular system","volume":"161","author":"A Labastida-Ram\u00edrez","year":"2020","journal-title":"Pain"},{"issue":"03","key":"ref13","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/bph.15699","article-title":"The selective 5-HT1F receptor agonist lasmiditan inhibits trigeminal nociceptive\n                    processing: implications for migraine and cluster headache","volume":"179","author":"M Vila-Pueyo","year":"2022","journal-title":"Br J Pharmacol"},{"issue":"03","key":"ref14","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1124\/jpet.111.179606","article-title":"Toward selective drug development for the human 5-hydroxytryptamine 1E receptor:\n                    a comparison of 5-hydroxytryptamine 1E and 1F receptor structure-affinity\n                    relationships","volume":"337","author":"M T Klein","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"issue":"01","key":"ref15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/s0014-2999(98)00336-7","article-title":"Human 5-HT1F receptor-stimulated [35S]GTPgammaS binding: correlation with\n                    inhibition of guinea pig dural plasma protein extravasation","volume":"352","author":"D B Wainscott","year":"1998","journal-title":"Eur J Pharmacol"},{"issue":"06","key":"ref16","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.31925\/farmacia.2023.6.15","article-title":"Lasmiditan nanoemulsion based in situ gel intranasal dosage form: formulation,\n                    characterization and in vivo study","volume":"71","author":"S H Jaber","year":"2023","journal-title":"Farmacia"},{"issue":"01","key":"ref17","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/jcph.2328","article-title":"Investigation of the effect of lasmiditan on the pharmacokinetics of\n                    P-glycoprotein and breast cancer resistance protein substrates","volume":"64","author":"D Luffer-Atlas","year":"2024","journal-title":"J Clin Pharmacol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"24","DOI":"10.56831\/PSMPH-04-143","article-title":"Lasmiditan: A novel drug for the acute treatment of migraine","volume":"4","author":"N Bhatti","year":"2024","journal-title":"Health"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.2147\/DDDT.S380440","article-title":"Profile of lasmiditan in the acute treatment of migraine in adults: design,\n                    development, and place in therapy","volume":"17","author":"C C Anderson","year":"2023","journal-title":"Drug Des Devel Ther"},{"issue":"03","key":"ref20","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3999\/jscpt.51.119","article-title":"Safety, tolerability, and pharmacokinetics of Lasmiditan in healthy Japanese and\n                    Caucasian subjects","volume":"51","author":"M Komori","year":"2020","journal-title":"Rinsho Jpn J Clin Pharmacol Ther"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2024.2371382","article-title":"Safety profile of lasmiditan: a retrospective post-marketing pharmacovigilance\n                    study based on the real-world data of FAERS database","volume":"10","author":"X Wan","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/17425255.2019.1578749","article-title":"Pharmacokinetics and pharmacodynamics of new acute treatments for migraine","volume":"15","author":"C Lupi","year":"2019","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1080\/03007995.2020.1808780","article-title":"Lasmiditan in patients with common migraine comorbidities: A post hoc efficacy\n                    and safety analysis of two phase 3 randomized clinical trials","volume":"36","author":"D B Clemow","year":"2020","journal-title":"Curr Med Res Opin"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s10194-024-01904-1","article-title":"Efficacy of Lasmiditan, Rimegepant and Ubrogepant for acute treatment of\n                    migraine in triptan insufficient responders: systematic review and network\n                    meta-analysis","volume":"25","author":"W Laohapiboolrattana","year":"2024","journal-title":"J Headache Pain"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/978-3-030-95334-8_8","volume-title":"Lasmiditan","author":"S Parikh","year":"2022"},{"issue":"04","key":"ref28","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3390\/toxins13040291","article-title":"Vasoactive effects of acute ergot exposure in sheep","volume":"13","author":"R Yonpiam","year":"2021","journal-title":"Toxins"},{"issue":"02","key":"ref29","doi-asserted-by":"publisher","first-page":"144","DOI":"10.47583\/ijpsrr.2023.v80i02.021","article-title":"Lasmiditan, a novel abortive agent for migraine therapy \u2013 from triptans to\n                    ditans","volume":"80","author":"S Gaddam","year":"2023","journal-title":"Int J Pharm Sci Rev Res"},{"issue":"24","key":"ref30","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1212\/WNL.0000000000006641","article-title":"Lasmiditan is an effective acute treatment for migraine: a phase 3 randomized\n                    study","volume":"91","author":"B Kuca","year":"2018","journal-title":"Neurology"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1177\/0333102419864132","article-title":"Interim results of a prospective, randomized, open-label, phase 3 study of the\n                    long-term safety and efficacy of Lasmiditan for acute treatment of migraine (the\n                    GLADIATOR study","volume":"39","author":"J L Brandes","year":"2019","journal-title":"Cephalalgia"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s10194-012-0428-7","article-title":"The 5-HT1F receptor agonist Lasmiditan as a potential treatment of migraine\n                    attacks: a review of two placebo-controlled phase II trials","volume":"13","author":"P C Tfelt-Hansen","year":"2012","journal-title":"J Headache Pain"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1177\/0333102410375512","article-title":"Acute treatment of migraine with the selective 5-HT1F receptor agonist\n                    Lasmiditan\u2014a randomized proof-of-concept trial","volume":"30","author":"M D Ferrari","year":"2010","journal-title":"Cephalalgia"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1474-4422(12)70047-9","article-title":"Efficacy and tolerability of Lasmiditan, an oral 5-HT1F receptor agonist, for\n                    the acute treatment of migraine: a phase 2 randomized, placebo-controlled,\n                    parallel-group, dose-ranging study","volume":"11","author":"M F\u00e4rkkil\u00e4","year":"2012","journal-title":"Lancet Neurol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1016\/S1474-4422(12)70047-9","article-title":"Lasmiditan for the treatment of acute migraine: a review and potential role in\n                    clinical practice","volume":"11","author":"J C Oswald","year":"2018","journal-title":"J Pain Res"},{"issue":"07","key":"ref36","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1093\/brain\/awz134","article-title":"Phase 3 randomized, placebo-controlled, double-blind study of Lasmiditan for\n                    acute treatment of migraine","volume":"142","author":"P J Goadsby","year":"2019","journal-title":"Brain"},{"issue":"01","key":"ref37","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s10194-019-1044-6","article-title":"Lasmiditan for acute treatment of migraine in patients with cardiovascular risk\n                    factors: post-hoc analysis of pooled results from 2 randomized, double-blind,\n                    placebo-controlled, phase 3 trials","volume":"20","author":"R E Shapiro","year":"2019","journal-title":"J Headache Pain"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s10194-020-01088-4","article-title":"Trajectory of migraine-related disability following long-term treatment with\n                    Lasmiditan: results of the GLADIATOR study","volume":"21","author":"R B Lipton","year":"2020","journal-title":"J Headache Pain"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1177\/0333102419859313","article-title":"Sustained responses to Lasmiditan: results from post-hoc analyses of two phase 3\n                    randomized clinical trials for acute treatment of migraine","volume":"39","author":"E G Doty","year":"2019","journal-title":"Cephalalgia"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1177\/0333102421989232","article-title":"Randomized, controlled trial of Lasmiditan over four migraine attacks: findings\n                    from the CENTURION study","volume":"41","author":"M Ashina","year":"2021","journal-title":"Cephalalgia"},{"issue":"08","key":"ref41","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1177\/0333102419855080","article-title":"Safety findings from phase 3 Lasmiditan studies for acute treatment of migraine:\n                    results from SAMURAI and SPARTAN","volume":"39","author":"J H Krege","year":"2019","journal-title":"Cephalalgia"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1002\/hup.2732","article-title":"Effects of Lasmiditan on simulated driving performance: results of two\n                    randomized, blinded, crossover studies with placebo and active controls","volume":"35","author":"E M Pearlman","year":"2020","journal-title":"Hum Psychopharmacol"},{"issue":"03","key":"ref43","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/cpdd.781","article-title":"Lasmiditan: its development and potential use","volume":"9","author":"A E Macone","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.3390\/ijms20092288","article-title":"The serotonin syndrome: from molecular mechanisms to clinical practice","volume":"20","author":"J Francescangeli","year":"2019","journal-title":"Int J Mol Sci"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/cpdd.768","article-title":"Effects of Lasmiditan on cardiovascular parameters and pharmacokinetics in\n                    healthy subjects receiving oral doses of propranolol","volume":"9","author":"M Tsai","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s13311-018-0615-6","article-title":"Targeted 5-HT1F therapies for migraine","volume":"15","author":"M Vila-Pueyo","year":"2018","journal-title":"Neurotherapeutics"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s10194-019-1032-x","article-title":"Efficacy and safety of Lasmiditan in patients using concomitant migraine\n                    preventive medications: Findings from SAMURAI and SPARTAN, two randomized phase\n                    3 trials","volume":"20","author":"L S Loo","year":"2019","journal-title":"J Headache Pain"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/head.13549","article-title":"Effects of Lasmiditan when coadministered with sumatriptan: Results of a\n                    randomized, double-blind, crossover study in healthy subjects","volume":"59","author":"P H Berg","year":"2019","journal-title":"Headache"},{"key":"ref49","first-page":"95","article-title":"Multiple-ascending dose, safety, tolerability, pharmacokinetic, and drug-drug\n                    interaction study with Lasmiditan","volume":"60","author":"D Wilbraham","year":"2020","journal-title":"Headache"}],"container-title":["Drug Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2695-0263.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T23:37:44Z","timestamp":1763509064000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2695-0263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":47,"journal-issue":{"issue":"09","published-online":{"date-parts":[[2025,11,18]]},"published-print":{"date-parts":[[2025,11]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2695-0263","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2194-9379","2194-9387"],"issn-type":[{"value":"2194-9379","type":"print"},{"value":"2194-9387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,24]]}}}